Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders - Top-Institutions - MDSpire

Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders

  • By

  • David T. Liebers

  • Tianshe He

  • Rebecca A. Betensky

  • Chunlei Zheng

  • Kaitlin N. Swinnerton

  • Sean Jacobson

  • Linden Huhmann

  • Mary T. Brophy

  • Nhan V. Do

  • Paola Gilsanz

  • Ricardo S. Osorio

  • Nunzio Pomara

  • Antonio Convit

  • Donald C. Goff

  • Dan V. Iosifescu

  • Nathanael R. Fillmore

  • Jaime Ramos-Cejudo

  • June 30, 2026

  • 0 min

Share

Top Institutions in Psychiatry

Brief introduction explaining scope and methodology.

  • #1

    US Department of Veterans Affairs
    US Department of Veterans Affairs

    Washington, DC

    Key Differentiators

    • Psychiatry

  • #2

    VA Boston Research and Development Committee
    VA Boston Research and Development Committee

    Boston, MA

    Key Differentiators

    • Psychiatry

  • #3

    Taipei Medical University
    Taipei Medical University

    Taipei, Taiwan

    Key Differentiators

    • Psychiatry

Original Source(s)

Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders

  • by David T. Liebers, Tianshe He, Rebecca A. Betensky, Chunlei Zheng, Kaitlin N. Swinnerton, Sean Jacobson, Linden Huhmann, Mary T. Brophy, Nhan V. Do, Paola Gilsanz, Ricardo S. Osorio, Nunzio Pomara, Antonio Convit, Donald C. Goff, Dan V. Iosifescu, Nathanael R. Fillmore, Jaime Ramos-Cejudo

  • June 30, 2026

Related Content

Editorial: The heterogeneity of psychiatric symptoms and disorders

Associations of TNF-α, MIF, and cortisol with cognitive function in patients with bipolar disorder during acute manic episodes: a short-term follow-up study

Automated Speech-Based Modeling of Item-Level Symptom Severity in Schizophrenia